The European Commission approved similar biologics, quality, efficacy and safety, which is similar to currently available biopharmaceuticals in the approved indications are to demonstrate it has already approved similar biologics A comparable legal and regulatory approval pathway does not yet exist in the United States.

The company plans to launch the product – which will be Hospira’s first marketed similar biologic – in various EU countries from early 2008. As the world leader in generic injectables, Hospira is ready to bring high-quality, lower-cost similar biologics in patients We are pleased under these agreements, this milestone for this important medication, ‘says Michael Kotsanis, president, Europe, Middle East and Africa, Hospira. ‘Similar biologics like Retacrit can help provide safe, effective patient care, reducing while contributing to global health care costs ‘. – end of 2006, Hospira, STADA and BIOCEUTICALS Arzneimittel AG, STADA STADA announced, development, manufacturing and distribution agreements for epoetin zeta.We are glad pleased to announce new subset of data that on the left primary and three-vessel patient from the landmark SYNTAX trial, Although the only randomized study of its kind, the doctors with critical data delivered about the performance out of medicines stents stents in these very difficult patient populations, said Keith D. Dawkins, Senior Vice President and associate Chief Medical Officer Boston Scientific. We also plan to showcase additional details on the SYNTAX Score – developing a new scientific measure for anatomical complexity to offer as guideline for doctors examined treatments for the LM and 3VD patients. .. To announce Boston Scientific be a wide variety of safety and efficacy data on the TAXUS Express2 and second-generation TAXUS Liberte paclitaxel – eluting Coronary system, including the 12-month subgroup of data to patients left main and three-vessel illness from the SYNTAX trial, than compared coronary intervention with the the TAXUS Express2 the stent system to coronary bypass surgery at these complex patient populations.